Instrument Inactif

Autres langues Oragenics Inc OTC Bulletin Board

Actions

OGEN

US6840232036

Recherche biotechnologique et médicale

Autres langues

28/08	Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update
13/08	Oragenics: Q2 Earnings Snapshot
13/08	Oragenics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
07/07	Oragenics Achieves Full Activation of Australian Phase IIa Trial Network for ONP-002 and Advances U.S. Regulatory Pathway
07/07	Oragenics Says All Three Australian Concussion Trial Sites Enrolling Patients
07/07	Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling
06/07	Oragenics, Inc. Announces Appointment of John Spencer to Chief Financial Officer, Effective July 1, 2026
20/05	Oragenics to Present at Sidoti's Micro-Cap Virtual Investor Conference May 20-21
19/05	Oragenics : Investor Presentation - May 2026
19/05	Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21
18/05	ORAGENICS PROVIDES INVESTOR UPDATE
08/05	Oragenics: Q1 Earnings Snapshot
08/05	Oragenics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
07/05	Oragenics signs letter of intent to license Cardiodialysis(TM) technology from Sigyn Therapeutics to target TBI-induced systemic inflammation
07/05	Oragenics Inc - signs letter of intent to license Cardiodialysis from Sigyn Therapeutics - SEC filing
07/05	Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation
05/05	Oragenics activates second site in Phase IIa clinical trial of ONP-002 for concussion and mild traumatic brain injury.
05/05	Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.
05/05	Oragenics Inc Activates Second Site In Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury
20/04	Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
20/04	Oragenics Inc Reports 8 Study Drug Doses in Phase IIa Clinical Trial Of ONP-002 For Mild Traumatic Brain Injury
13/04	Oragenics, Inc. Doses First Patient In Phase IIa Clinical Trial Of ONP-002 For Mild Traumatic Brain Injury
13/04	Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
25/03	Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation
17/03	ORAGENICS FILES ANNUAL REPORT ON FORM 10-K